logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
C

Curtis Dunshee

arizona urology specialists
H指数:15
被引数:1,763

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study [European Journal of Cancer Volume 213, December 2024, 115078]

勘误：Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 的安全性分析，来自随机、安慰剂对照、III 期 TALAPRO-2 研究的结果 [European Journal of Cancer Volume 213, December 2024, 115078]

European Journal of Cancer
IF7.1
2025-11-130
PRE
Arun A. Azad; Karim Fizazi; Nobuaki Matsubara; Fred Saad; Ugo De Giorgi; Jae Young Joung; Peter C.C. Fong; Robert J. Jones; Stefanie Zschäbitz; Jan Oldenburg; Neal D. Shore; Curtis Dunshee; Joan Carles; Andre P. Fay; Xun Lin; Liza DeAnnuntis; Nicola Di Santo; Michael A. Zielinski; Neeraj Agarwal
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 男性患者的最终总生存结果：来自随机、安慰剂对照、III期 TALAPRO-2 试验的数据

lancet
IF0
2025-07-160
PRE
Neeraj Agarwal; Arun A Azad; Joan Carles; André P Fay; Nobuaki Matsubara; Cezary Szczylik; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Fred Saad; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Xun Lin; Cynthia G Healy; Matko Kalac; Dana Kennedy; Karim Fizazi
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Talazoparib 联合 enzalutamide 治疗 HRR 缺陷型转移性去势抵抗性前列腺癌的男性患者：来自随机、安慰剂对照的 III 期 TALAPRO-2 试验的最终总生存结果

lancet
IF0
2025-07-160
PRE
Karim Fizazi; Arun A Azad; Nobuaki Matsubara; Joan Carles; André P Fay; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Dingwei Ye; Xun Lin; Matko Kalac; A Douglas Laird; Dana Kennedy; Neeraj Agarwal
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study

Talazoparib联合enzalutamide治疗转移性去势抵抗性前列腺癌: 来自随机，安慰剂对照，III期TALAPRO-2研究的安全性分析

EUROPEAN JOURNAL OF CANCER
IF7.1
2024-12-010
OAAI
Azad, Arun A.; Fizazi, Karim; Matsubara, Nobuaki; Saad, Fred; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Jones, Robert J.; Zschaebitz, Stefanie; Oldenburg, Jan; Shore, Neal D.; Dunshee, Curtis; Carles, Joan; Fay, Andre P.; Lin, Xun; Deannuntis, Liza; Di Santo, Nicola; Zielinski, Michael A.; Agarwal, Neeraj
Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study

talazoparib和enzalutamide在先前接受过雄激素受体通路抑制剂（ARPI）或多西他赛的mCRPC患者中的疗效：来自TALAPRO-2研究两个队列的事后分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Agarwal, N.; Azad, A. A.; Galceran, J. C.; Fay, A. P.; Matsubara, N.; Szczylik, C.; De Giorgi, U.; Joung, J. Y.; Fong, P. C.; Voog, E.; Jones, R. J.; Shore, N. D.; Dunshee, C.; Zschaebitz, S.; Oldenburg, J.; Lin, X.; Laird, D.; Kalac, M.; Kennedy, D.; Fizazi, K.
Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer

TALAPRO-2研究结果的简明语言摘要: 塔拉唑帕利加恩扎鲁他胺与安慰剂加恩扎鲁他胺治疗晚期前列腺癌的比较

FUTURE ONCOLOGY
IF2.6
2024-07-121
OAAI
Agarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, Andre P.; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; Giorgi, Ugo De; Joung, Jae Young; Fong, Peter C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Zohren, Fabian; Fizazi, Karim
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial (vol 30, pg 257, 2024)

一线talazoparib联合恩扎鲁他胺治疗HRR缺乏的转移性去势抵抗性前列腺癌: 3期TALAPRO-2试验 (第30卷，257页，2024页)

NATURE MEDICINE
IF50
2024-01-311
OAAI
Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P.; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Laird, A. Douglas; Zohren, Fabian; Agarwal, Neeraj
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

一线talazoparib联合恩扎鲁他胺治疗HRR缺乏的转移性去势抵抗性前列腺癌: 3期TALAPRO-2试验

NATURE MEDICINE
IF50
2023-12-0440
OAAI
Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P.; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschaebitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Laird, A. Douglas; Zohren, Fabian; Agarwal, Neeraj
Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status

Talazoparib (TALA) 加恩扎鲁他胺 (ENZA) 治疗转移性去势抵抗性前列腺癌 (mCRPC): 通过同源重组修复 (HRR) 状态对来自TALAPRO-2的所有参与者队列进行亚组分析

ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Matsubara, N.; Fizazi, K.; Azad, A. A.; Galceran, J. Carles; Fay, A. P.; De Giorgi, U. F. F.; Joung, J. Y.; Fong, P. C.; Voog, E.; Jones, R. J.; Shore, N. D.; Dunshee, C.; Zschaebitz, S.; Karsh, L. I.; Barthelemy, P.; Lin, X.; Healy, C. G.; Di Santo, N.; Zohren, F.; Agarwal, N.
Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA: Results from a phase III (TALAPRO-2) study

接受talazoparib (TALA) 加恩扎鲁他胺 (ENZA) 与安慰剂 (PBO) 加ENZA的转移性去势抵抗性前列腺癌 (mCRPC) 和同源重组修复 (HRR) 突变男性的患者报告结局 (PROs): III期 (TALAPRO-2) 研究的结果

ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OA
Fay, A. P.; Fizazi, K.; Matsubara, N.; Azad, A. A.; Saad, F.; De Giorgi, U. F. F.; Joung, J. Y.; Fong, P. C.; Jones, R. J.; Zschaebitz, S.; Oldenburg, J.; Shore, N. D.; Dunshee, C.; Galceran, J. Carles; Cislo, P.; Chang, J.; Healy, C. G.; Niyazov, A.; Agarwal, N.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Talazoparib联合恩扎鲁他胺治疗一线转移性去势抵抗性前列腺癌 (TALAPRO-2): 一项随机、安慰剂对照、3期临床试验

LANCET
IF88.5
2023-07-01181
PRE
Agarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, Andre P.; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal; Dunshee, Curtis; Zschaebitz, Stefanie; Oldenburg, Jan; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Zohren, Fabian; Fizazi, Karim

研究方向

暂未获取到该数据
N
Neal D. Shore
H 指数:84论文数:1,298被引数:4.5万
A
Arun Azad
H 指数:51论文数:521被引数:1.3万
A
André P. Fay
H 指数:33论文数:256被引数:6,516
J
Joan Carles
H 指数:55论文数:717被引数:2.0万
K
Karim Fizazi
H 指数:123论文数:1,539被引数:8.3万
X
Xun Lin
H 指数:30论文数:130被引数:4,955
R
Robert J. Jones
H 指数:67论文数:431被引数:2.9万
U
Ugo De Giorgi
H 指数:79论文数:981被引数:2.9万
P
Peter C.C. Fong
H 指数:42论文数:187被引数:1.3万
N
Nobuaki Matsubara
H 指数:39论文数:463被引数:1.2万